RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Learning from everyday use of an apomorphine pump

Researchers follow people using ONAPGO, which delivers apomorphine under the skin, to learn about their experiences in everyday care.

Learning by observing or collecting information · Study reference: NCT07219927

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2025-03-31
Main measurements finished (planned)
2027-08-01
Study finished (planned)
2027-08-01

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age 18 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: Participant has received a prescription for ONAPGO™ according to the standard of care. Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form. The HCP/Investigator determines the participant is an appropriate study participant. Participant is able and willing to provide informed consent (or informed assent form \[IAF\], as applicable) and signs the consent form on the Enrollment Day. Exclusion Criteria: Did not receive a prescription for ONAPGO™. Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study. Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron. Known hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).
Full study name & original research details

Official study title

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Short title used by the registry

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

Original description

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Further description from the registry

This observational study includes an Enrollment Day (participants enrolled any time between their prescription for the infusion and ONAPGO initiation); a Baseline Period (prior to ONAPGO initiation which includes in-home education on the use of ONAPGO by the Clinical Nurse Navigator \[CNN\] according to standard practice for patients with PD-prescribed ONAPGO); Dose Initiation, Titration, and Optimization per Prescription Periods; a Maintenance Period; Maintenance CNN standard of care visits; and an End-of-Study (EOS)/Discontinuation Visit.

Conditions reported: Parkinson Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Observational
Interventions
Observational study
Phases
Not reported
Sponsor
Supernus Pharmaceuticals, Inc.
Start date reported by registry
2025-03-31 (actual)

Registry updated: 2025-10-22 · Status last verified by the registry submitter: 2025-10

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Mindy Grall, PhD ANP-BC · 18663980833 · mgrall@supernus.com

Supernus Supernus · 18663980833

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Parkinson's Disease and Movement Disorders Center - Orange County (South)

Aliso Viejo, California, United States

Recruiting

Mindy Bixby, D.O.

Mindy Bixby, D.O.

Parkinson's Disease and Movement Disorders Center - Orange County (North)

Irvine, California, United States

Recruiting

Sandeep Thakkar, D.O.

Sandeep Thakkar, D.O.

Parkinson's Research Centers of America - Palo Alto

Palo Alto, California, United States

Recruiting

Salima Brillman, MD

Salima Brillman, MD

Parkinson's Disease & Movement Disorders Center of Boca Raton

Boca Raton, Florida, United States

Recruiting

Stuart Isaacson, MD

Stuart Isaacson, MD

Parkinson's Disease and Movement Disorders Center - Long Island

Commack, New York, United States

Recruiting

David Kreitzman, M.D.

David Kreitzman, M.D.

Facility not reported

United States

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.